Sign in
4

Changes in Ownership

TEVA PHARMACEUTICAL INDUSTRIES LTD Filed Acc 0001209191-21-009633

Executive VP, Global R&D sold 29,496 shares at $12.69 ($374,437)

  • Executive VP, Global R&D acquired 67,852 shares (grant or award)
  • Executive VP, Global R&D acquired 16,120 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Fridriksdottir Hafrun · Executive VP, Global R&D

Table I: Non-derivative

4 lines
Date Transaction Shares Price Value Owned after D/I
2021-02-09 Exercise or conversion : show line 1 in the form +16,120 61,680.51 D
2021-02-09 Grant or award : show line 2 in the form +67,852 129,532.51 D
2021-02-09 Sale : show line 3 in the form −5,857 $12.69 $74,352 123,675.51 D
2021-02-09 Sale : show line 4 in the form −23,639 $12.69 $300,085 100,036.51 D
Open-market sales · 29,496 sh · avg $12.69 · $374,437

Table II: Derivative

2 lines
Date Transaction Shares Owned after D/I
2021-02-09 Exercise or conversion : show line 5 in the form Restricted Share Units −16,120 16,121 D
2021-02-09 Grant or award : show line 6 in the form Restricted Share Units +37,884 37,884 D
Loading xslF345X03/doc4.xml…